Bank Of New York Mellon Corp Verrica Pharmaceuticals Inc. Transaction History

Bank Of New York Mellon Corp

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.09 - $3.39 $24,028 - $38,974	11,497 New	11,497 $31,000
Q2 2022 Aug 15, 2022	SELL	$1.81 - $8.93 $61,981 - $305,798	-34,244 Reduced 74.76%	11,563 $22,000
Q1 2022 May 11, 2022	SELL	$7.59 - $9.49 $948 - $1,186	-125 Reduced 0.27%	45,807 $372,000
Q4 2021 Feb 11, 2022	BUY	$9.1 - $13.36 $6,643 - $9,752	730 Added 1.61%	45,932 $420,000
Q3 2021 Nov 12, 2021	BUY	$9.55 - $13.96 $28,640 - $41,866	2,999 Added 7.11%	45,202 $565,000
Q2 2021 Aug 11, 2021	SELL	$9.77 - $15.33 $18,084 - $28,375	-1,851 Reduced 4.2%	42,203 $476,000
Q1 2021 May 13, 2021	SELL	$10.51 - $17.46 $70,742 - $117,523	-6,731 Reduced 13.25%	44,054 $667,000
Q4 2020 Feb 09, 2021	BUY	$7.41 - $12.63 $139,315 - $237,456	18,801 Added 58.78%	50,785 $584,000
Q3 2020 Nov 12, 2020	SELL	$6.16 - $10.3 $5,229 - $8,744	-849 Reduced 2.59%	31,984 $247,000
Q2 2020 Aug 12, 2020	SELL	$9.02 - $15.12 $26,248 - $43,999	-2,910 Reduced 8.14%	32,833 $361,000
Q4 2019 Feb 14, 2020	BUY	$13.08 - $17.43 $1,137 - $1,516	87 Added 0.24%	35,743 $567,000
Q3 2019 Nov 07, 2019	SELL	$8.65 - $14.81 $16,884 - $28,909	-1,952 Reduced 5.19%	35,656 $526,000
Q2 2019 Aug 12, 2019	BUY	$7.1 - $11.62 $86,605 - $141,740	12,198 Added 48.0%	37,608 $437,000
Q1 2019 May 14, 2019	BUY	$7.95 - $14.07 $69,546 - $123,084	8,748 Added 52.5%	25,410 $275,000
Q4 2018 Feb 11, 2019	BUY	$6.75 - $16.12 $31,596 - $75,457	4,681 Added 39.07%	16,662 $136,000
Q3 2018 Nov 09, 2018	BUY	$13.94 - $19.88 $167,015 - $238,182	11,981 New	11,981 $0

17.4M

6.1K

6.3K

Ticker VRCA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,094,100
Market Cap $327M
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.